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Abstract
Background: The Coxsackie and adenovirus receptor (CAR) has a restricted expression pattern
in the adult. In skeletal muscle, although CAR is expressed in immature fibers, its transcript levels
are barely detectable in mature muscle. This is in contrast to the robust expression observed in
the heart. However, both heart and skeletal muscle are susceptible to infection with the Coxsackie
B virus which utilizes primarily CAR for cellular internalization. The specific point of viral entry in
skeletal and heart muscle remains unknown.
Results: Using antibodies directed against the extracellular and the cytoplasmic domains of CAR,
we show CAR in normal human and mouse skeletal muscle to be a novel component of the
neuromuscular junction. In cardiac muscle, CAR immunoreactivity is observed at the level of
intercalated discs. We demonstrate a single isoform of CAR to be expressed exclusively at the
human neuromuscular junction whereas both predominant CAR isoforms are expressed at the
intercalated discs of non-diseased human heart.
Conclusion: The localization of CAR to these important junctional complexes suggests that CAR
may play both a structural and a regulatory role in skeletal and cardiac muscle, and that these
complexes may serve as a point of entry for Coxsackie B virus.
Background
The Coxsackie and adenovirus receptor (CAR) [1,2], a
transmembrane protein of the immunoglobulin super-
family, serves as a receptor for adenovirus (Ad) subgroups
A, C, D, E and F [3] as well as Coxsackie B viruses (CVB)
[4]. CAR is a highly conserved protein with two predomi-
nant isoforms, produced through differential splicing,
and having cytoplasmic domains of either 107 residues
(ending in SIV) or 94 residues (ending in TVV) [2,5]. The
extracellular domain mediates homophilic cell adhesion
[6-8] and ectopically-expressed CAR localizes to homo-
typic intercellular contacts [8]. The expression of CAR is
regulated developmentally [6,9-12] as well as in a tissue-
specific manner [2,5]. To date, most studies on CAR
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expression in the adult have resorted to analysis of tran-
script levels. These have revealed that the pattern of tissue-
specific expression differs between humans and mice. In
humans, a predominant transcript of ~6 – 6.5 kb is
observed in heart, testis, prostate and pancreas while
much less expression is detected in liver, brain, colon and
small intestine. In the mouse on the other hand, the most
abundant expression is in liver, kidney, lung and heart.
Interest in CAR stems from its function as the primary
high affinity receptor for Ad serotype 5, the most com-
monly used adenoviral vector in gene therapy protocols.
CAR expression is the main determinant in gene transfer
to normal tissue as ectopic expression of CAR in trans-
genic mice leads to several magnitudes of increase in ade-
novirus transducibility of tissues that are otherwise
refractory to Ad-mediated gene expression [13-17]. As
well, although decay accelerating factor (DAF, CD55) was
the first described CVB receptor [18,19], CAR is necessary
and sufficient for CVB infection in vitro [20]. Thus, the
expression levels of CAR may also govern the susceptibil-
ity to CVB diseases and the pathological consequences of
CVB viral infection. In this context, acute viral myocarditis
and myositis are inflammatory diseases affecting cardiac
and skeletal muscle that can result from infection by the
Coxsackie B virus. In both humans and rodents, heart is
among the tissues showing the greatest abundance of CAR
transcript while its transcripts are barely detectable in skel-
etal muscle even with the more sensitive reverse-tran-
scriptase (RT)-PCR-based assay [21]. In contrast to heart,
DAF expression is absent in mature skeletal muscle [22].
Despite the absence of DAF and low CAR transcript levels,
skeletal muscle is nevertheless susceptible to Coxsackie
virus-induced myositis. Indeed, human patients suffering
from inflammatory muscle diseases have tested positive
for CBV RNA [23]. This suggests that the low CAR tran-
script level in skeletal muscle may produce functional
receptor. Therefore, to examine CAR localization in skele-
tal and cardiac muscle, we used antibodies directed
against the extracellular domain of CAR [21] as well as
antibodies that can differentiate between the two major
CAR isoforms [24] with alternate 3' splicing [ending in the
amino acids SIV or TVV] [2,5] [Fig. 1].
Results and Discussion
To immunolocalize CAR, frozen sections of normal
human muscle biopsies were probed with polyclonal anti-
bodies raised against the extracellular domain of CAR [21]
[ab 2240], or against the cytoplasmic tail, antibodies
which specifically recognize the two predominant iso-
forms of human CAR (referred to as SIV [ab RP291] and
TVV [ab RP194] respectively) [24]. We localized CAR
exclusively to the neuromuscular junction in human skel-
etal muscle (Fig. 2) where CAR immunoreactivity coin-
cided with acetylcholine receptors as revealed by α-
bungarotoxin binding. Similarly, in mature murine skele-
tal muscle, CAR expression was restricted to the neu-
romuscular junction (Fig. 3). Interestingly, we find CAR
expression at the neuromuscular junction to be isoform
specific, with the CAR SIV isoform accounting for all CAR
immunoreactivity (Fig. 2G). In contrast, the TVV isoform
is present in the vasculature (Fig. 2I). CAR is therefore
identified as a novel component of the adult neuromuscu-
lar junction, joining other homotypic cell adhesion mole-
cules such as N-cadherin and neural cell adhesion
molecule (N-CAM) which have been localized previously
to this specialized site. As with NCAM [25], although CAR
is uniformly expressed in immature mouse muscle (data
Depiction of the CAR sequences recognized by the anti-C-terminal antibodies Figure 1
Depiction of the CAR sequences recognized by the anti-C-terminal antibodies. The chicken antibody ChCT was 
raised against a fusion protein containing C-terminal sequence common to both CAR isoforms (from aa 259 – 339). The rabbit 
antibodies (RP291 and RP194) were raised against peptides that were specific to each isoform. The diagram does not show the 
immunogen of the rabbit antibody 2240 which is the extracellular N-terminal domain of murine CAR. Note that each antibody 
has a distinct recognition sequence. TM – transmembrane sequence.
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not shown), its expression becomes downregulated
within a few weeks of birth [21] and its localization is con-
fined to the neuromuscular junction. As well, in skeletal
muscle undergoing regeneration, as is the case in the dys-
trophic mdx mouse, CAR is re-expressed [21] as is NCAM
[26].
Immunolocalization of CAR to the neuromuscular junction in human skeletal muscle Figure 2
Immunolocalization of CAR to the neuromuscular junction in human skeletal muscle. Frozen sections of human 
muscle were incubated with Alexa Fluor-conjugated α-bungarotoxin and antibodies to CAR as described in Materials and 
Methods. Panels A and D show α-bungarotoxin staining of acetylcholine receptors at neuromuscular junctions (green). Panel 
B shows immunofluorescent staining of the section in panel A with a polyclonal antibody (ab 2240) to the extracellular domain 
of CAR (red). Panel E shows immunofluorescent staining of the section in panel D with a mixture of the isoform-specific C-
terminal antibodies RP194 and RP 291 (red). Panel C is a merge of panels A and B. Panel F is a merge of panels D and E. 
These merges [C, F] show that CAR colocalizes with α-bungarotoxin at neuromuscular junctions (in yellow). Of the two C-
terminal antibodies, only RP291 (G) demonstrates the typical neuromuscular junction staining while signal is absent when sec-
tions are incubated under similar conditions with RP194 (H) although RP194 does label blood vessels (I). Sections incubated 
with secondary antibody alone did not reveal any signals (J). Bar = 25 µm (A, D); 50 µm (G, I).
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CAR has been suggested to serve as a structural compo-
nent at the intercalated discs in murine cardiac muscle [8]
and recently confirmed to reside primarily at the interca-
lated discs in both rat heart and neonatal cultured cardio-
myocytes of the rodent [12]. Using antibodies directed to
the specific SIV and TVV isoforms of the receptor as
described above, we localized CAR to the intercalated
discs (Fig. 4), demonstrating for the first time expression
of both receptor isoforms in human and murine heart. To
confirm the presence of both isoforms, murine cardiac
muscle homogenates were analyzed by SDS-PAGE fol-
lowed by electrotransfer to nitrocellulose membranes.
This immunoblot analysis revealed the presence of both
the SIV and TVV isoforms (Fig. 5A). Furthermore, when
murine cardiac muscle homogenates were immunopre-
cipitated with either RP194 or RP 291 rabbit polyclonal
antibodies, Western blot analysis of the resultant fractions
with a chicken antibody against CAR C-terminal domain
showed a single 46 kDa band (Fig. 5B), confirming the
specificity of the antibodies for CAR.
Both of the cytoplasmic variants contain a PDZ recogni-
tion motif at their distal end, implicating CAR as a puta-
tive member of multiprotein complexes. This is indeed
the case in polarized epithelial cells in which CAR is
expressed at the tight junction where it associates with the
tight junction scaffolding protein ZO-1 [8] and contrib-
utes to maintenance of transepithelial resistance. The
Immunolocalization of CAR to the neuromuscular junction in mouse skeletal muscle Figure 3
Immunolocalization of CAR to the neuromuscular junction in mouse skeletal muscle. Frozen sections of mouse 
muscle were incubated with Alexa Fluor-conjugated α-bungarotoxin and antibodies to CAR as described in Materials and 
Methods. Panels A and D show α-bungarotoxin staining of acetylcholine receptors at neuromuscular junctions (green). Panel 
B shows immunofluorescent staining of the section in panel A with a polyclonal antibody (ab 2240) to the extracellular domain 
of CAR (red). Panel E shows immunofluorescent staining of the section in panel D with a chicken polyclonal antibody (ChCT) 
directed against a C-terminal portion of CAR conserved in both CAR isoforms (red). Panel C is a merge of panels A and B. 
Panel F is a merge of panels D and E. These merges [C, F] show that CAR colocalizes with α-bungarotoxin at murine neu-
romuscular junctions (in yellow). Sections incubated with the secondary antibodies alone did not give any signal – anti-rabbit 
IgG [G], anti-chicken IgY [H]. Bar = 35 µm
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Immunolocalization of CAR to intercalated discs in human and murine cardiac muscle Figure 4
Immunolocalization of CAR to intercalated discs in human and murine cardiac muscle. Human [A, B] and murine 
[C, D] cardiac muscle sections were reacted with the polyclonal anti-C-terminal antibodies RP194 [A, C] and RP291 [B, D]. 
Note the intense staining of both isoforms at the human intercalated discs (arrow) [A, B] and murine intercalated discs [C, 
D]. Neither the human cardiac tissue [E] nor the murine cardiac muscle [F] gave any signal when incubated with the anti-rabbit 
IgG. Bar = 10 µm (A, E); 30 µm (C, F).
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localization of CAR to cardiac intercalated discs is in
agreement with CAR having a structural or regulatory role
as a transmembrane member of junctional complexes.
The intercalated discs are composed of at least three struc-
turally distinct cellular junctions – desmosomes, the
adherens junctions, and gap junctions [27]. The SIV and
TVV isoforms may localize to separate components of the
intercalated disc, or given that CAR has been implicated as
a transmembrane component in tight junctions [8], both
isoforms may be localized to the adherens junction, a
structure analogous to tight junctions.
It is interesting that a correlation can be drawn between
disease incidence and expression levels of the CAR recep-
tor. Cases of viral myocarditis in the human population
outnumber those of myositis. This may be attributable to
the difference of endogenous CAR expression between the
two tissues. Considering that induction of CAR accompa-
nies myocarditis [28] and its dramatic upregulation has
recently been demonstrated in patients suffering from
multiple diseases of the heart [29] including dilated cardi-
omyopathy, a pathological phenotype linked to persistent
acute myocarditis, upregulation of the receptor may
render the heart even more susceptible to further viral
infection. Conversely, the low level of endogenous CAR
expression in skeletal muscle may safeguard against the
wide-spread viral infection seen in myocarditis and may
be responsible for the less severe clinical features of
myositis.
Conclusions
CAR is a novel member of the neuromuscular junction. In
cardiac muscle, both CAR isoforms are found at the inter-
calated discs. The localization of CAR to these important
junctional complexes suggests that CAR may play both a
structural and a regulatory role in skeletal and cardiac
muscle, and that these complexes may serve as a point of
entry for Coxsackie B virus.
Methods
Antibodies
Figure 1 depicts the sequences used as immunogen to gen-
erate the various antibodies. There was no overlap (i.e.
common epitopes) between any of the antibodies. The
rabbit polyclonal antibodies used in this study were
described previously [21,24]. Briefly, the N-terminal pol-
yclonal antibody (ab 2240) was prepared against a His-
tagged fusion protein which encoded amino acid residues
22–208 of the extracellular domain of mouse CAR [21].
This antiserum cross-reacts with human CAR on Western
blots and in indirect immunofluorescence. The two C-ter-
minal polyclonal antibodies [24] were generated using
peptides encompassing the last 13 amino acids of the two
predominant human CAR isoforms [2,5]. Antiserum
RP194 was raised against the sequence FKYAYKTDGITVV
while RP291 was raised against the sequence VMIPAQSK-
DGSIV. Both these antisera cross-react with the mouse
CAR homologs (the peptides are conserved 100%
between the two species [30]). All antisera were affinity
purified prior to use.
Murine cardiac muscle homogenates express both isoforms  of CAR Figure 5
Murine cardiac muscle homogenates express both 
isoforms of CAR. A. Immunoblot analysis of cardiac mus-
cle homogenates (10 µg) reveals that a single polypeptide of 
46 kDa is detected by the anti-C-terminal antibodies recog-
nizing the two different CAR isoforms (RP194 and RP291). 
B. Murine cardiac homogenates were immunoprecipitated 
with either RP194 (lanes 1,2) or RP291 (lanes 3,4) followed 
by immunoblotting with the chicken ChCT antibody that rec-
ognizes the C-terminal portion of CAR that is common to 
both isoforms. The ChCT antibody detected as a single band 
the increasing amounts of CAR that was immunoprecipitated 
with increasing amounts of the rabbit polyclonal antibodies (2 
µl, lanes 1,3; 4 µl, lanes 2,4).
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To raise the chicken anti-CAR antibody (ChCT), purified
His-tagged fusion protein encoding the C-terminal por-
tion of CAR that is common to both isoforms (amino
acids 259–339) was emulsified in an equal volume of
TiterMax Gold adjuvant (CytRx Corp., Norcross, GA) and
injected intramuscularly into chickens. One month post-
injection, IgY antibodies to CAR were obtained from the
eggs of injected chickens and subjected to affinity
purification.
Immunocytochemistry
Immunolabelling was performed using standard tech-
niques. Briefly, frozen sections (5 µm) of normal human
skeletal and cardiac muscle biopsies, murine skeletal and
cardiac muscle were fixed in 2% paraformaldehyde (pH
6.8) for 1–2 minutes, followed by overnight incubation at
4°C with the primary antibodies (a 1:30 dilution was
used for ab 2240, and 1:200 dilution for the abs RP291
and RP194, in blocking solution made of 3% bovine
serum albumin and 0.05% Tween-20 in phosphate-buff-
ered saline). Incubation with a mouse anti-rabbit biotin-
conjugated secondary ab (1:120; Jackson Immunore-
search Laboratories, West Grove, PA) was followed by Cy-
3-conjugated streptavidin (1:1000; Jackson Immunore-
search Laboratories). Controls consisted of sections
treated in the absence of primary antibody. Neuromuscu-
lar junctions were revealed with Alexa-488-conjugated-α-
bungarotoxin [α BTX] (1:40) (Molecular Probes, Eugene,
OR). Slides were viewed on a Leica microscope-based
imaging system using OpenLab imaging software (Quo-
rum Technologies, St Catharines, ON).
Western blot analysis and immunoprecipitation
Cardiac muscle tissue was homogenized in extraction
buffer [1% Triton X-100; 0.1 mM EDTA; 0.1 mM EGTA; 50
mM Tris-HCl; pH 8.0; with protease inhibitors (Roche)] at
4°C. After a 30 second sonication, samples were centri-
fuged at 3000 × g for 30 seconds at 4°C. Protein samples
(10 µg) were anayzed by sodium dodecyl sulfate-polyacr-
ylamide gel electrophoresis (SDS-PAGE) using 10% (w/v)
polyacrylamide gels, followed by electrotransfer to nitro-
cellulose. The blots were blocked in 10% BLOTTO (skim
milk powder) in Tris buffered saline – Tween 20 (TBS-T)
for 45 minutes at room temperature. Anti-CAR antibody
was added in 10% BLOTTO at a dilution of 1:2500. Fol-
lowing incubation with peroxidase-labeled goat-anti-rab-
bit secondary antibody (Jackson Immunoresearch
Laboratories), the signal was visualized by enhanced
chemiluminescence (Amersham Pharmacia Biotech, Baie
d'Urfe, QC).
Immunoprecipitation was carried out on cardiac muscle
homogenates that had been pre-cleared with Protein-A
Agarose slurry (Sigma), followed by overnight incubation
at 4°C with RP291 or RP194. The samples were further
incubated with Protein-A Agarose for 2 hours, washed
twice with extraction buffer and then eluted with 2 X Lae-
mmli SDS sample buffer with 5% mercaptoethanol. Fol-
lowing SDS-PAGE and electrotransfer, nitrocellulose
membranes were probed with a primary polyclonal
chicken anti-CAR (ChCT) in blocking solution (diluted
1:500) overnight at 4°C. Signal was revealed following
incubation with a peroxidase-conjugated donkey anti-
chicken IgY (Jackson Immunoresearch Laboratories) at a
dilution of 1:2500 for 40 minutes, and enhanced
chemiluminescence.
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